Ascendis Will Take On Daily Genotropin With Weekly Skytrofa

Company Will Try To Assert Superiority Claim

Ascendis’s growth hormone deficiency drug Skytrofa will offer a convenience advantage as a weekly injectable. But the label does not clearly delineate superiority shown in a Phase III trial.

FDA approved background, 3D rendering, blue street sign
Ascendis gets its first drug approval for weekly injectable growth hormone product

Ascendis Pharma A/S obtained its first product approval on 25 August with a US Food and Drug Administration thumbs-up for its weekly injectable formulation of somatropin in pediatric growth hormone deficiency. The Denmark-based firm offered few details about launch plans other than it anticipates introducing the product to the market during the fourth quarter and will seek “premium responsible pricing” in discussions with payers.

Analysts hailed the approval as an important validation for Ascendis’s TransCon (transient conjugation) controlled-release delivery technology. In the case of the pGHD product Skytrofa (lonapegsomatropin-tcgd), the technology provides patients with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Scrip

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By 

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Tech Convergence, Quality Data Needed To Accelerate Korea’s AI-Powered R&D

 
• By 

AI-powered drug development was a major topic at the recent Bio Korea meeting, where experts discussed how the technology is changing R&D activities and the challenges being faced by Korean firms as they look to catch up with their global competitors.

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs

 

Data from several closely watched solid tumor drug trials – some considered practice-changing – are scheduled for presentation at the meeting, including for AstraZeneca and Daiichi’s Enhertu.